111 related articles for article (PubMed ID: 22430264)
1. A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Nozières C; Walter T; Joly MO; Giraud S; Scoazec JY; Borson-Chazot F; Simon C; Riou JP; Lombard-Bohas C
Eur J Endocrinol; 2012 Jun; 166(6):1107-11. PubMed ID: 22430264
[TBL] [Abstract][Full Text] [Related]
2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
3. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Saranga-Perry V; Morse B; Centeno B; Kvols L; Strosberg J
Neuroendocrinology; 2013; 97(4):318-21. PubMed ID: 23296364
[TBL] [Abstract][Full Text] [Related]
5. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
[TBL] [Abstract][Full Text] [Related]
6. [Familial paraganglioma syndrome: phenotype and relevance of a new SDHB mutation].
Díaz-Soto G; Serrano Morte A; Rodríguez Martín C; García-Talavera P; Abril CM; Puig-Domingo M
Med Clin (Barc); 2013 May; 140(10):453-7. PubMed ID: 23434467
[TBL] [Abstract][Full Text] [Related]
7. Novel mutation (L157X) in the succinate dehydrogenase B gene (SDHB) in a Japanese family with abdominal paraganglioma following lung metastasis.
Saito T; Saito Y; Matsumura K; Tsubota Y; Maniwa T; Kaneda H; Minami K; Sakaida N; Uemura Y; Kawa G; Yamamoto N; Fujii Y; Isobe K; Kawakami Y; Matsuda T; Takekoshi K
Endocr J; 2009; 56(3):451-8. PubMed ID: 19261994
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
9. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
10. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
11. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.
Brouwers FM; Eisenhofer G; Tao JJ; Kant JA; Adams KT; Linehan WM; Pacak K
J Clin Endocrinol Metab; 2006 Nov; 91(11):4505-9. PubMed ID: 16912137
[TBL] [Abstract][Full Text] [Related]
12. Targeting NAD
Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
[No Abstract] [Full Text] [Related]
13. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
15. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.
Burnichon N; Rohmer V; Amar L; Herman P; Leboulleux S; Darrouzet V; Niccoli P; Gaillard D; Chabrier G; Chabolle F; Coupier I; Thieblot P; Lecomte P; Bertherat J; Wion-Barbot N; Murat A; Venisse A; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP;
J Clin Endocrinol Metab; 2009 Aug; 94(8):2817-27. PubMed ID: 19454582
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
18. Succinate Dehydrogenase B Subunit-Negative Jugular Foramen Paraganglioma Manifesting Malignant Progression with Pseudohypoxia-Related Atypical Uptake of [
Ohtake M; Tateishi K; Murata H; Nagashima Y; Yamanaka S; Yamamoto T
World Neurosurg; 2018 Jun; 114():47-52. PubMed ID: 29510284
[TBL] [Abstract][Full Text] [Related]
19. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
[TBL] [Abstract][Full Text] [Related]
20. Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma.
Majumdar S; Friedrich CA; Koch CA; Megason GC; Fratkin JD; Moll GW
Pediatr Blood Cancer; 2010 Mar; 54(3):473-5. PubMed ID: 19927285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
